Amy M. Scurlock
Professor
faculty
Peds Pediatrics, College of Medicine
Research Areas
Biography and Research Information
OverviewAI-generated summary
Amy M. Scurlock is a Professor of Pediatrics at the University of Arkansas for Medical Sciences (UAMS) and Arkansas Children’s Hospital (ACH) and Research Institute. Her clinical work involves caring for patients with a range of allergic and immunologic conditions, with specific interests in food allergy and primary immunodeficiency. She emphasizes patient- and family-centered care, integrating evidence-based management with consideration for social determinants of health.
Dr. Scurlock's research focuses on clinical trials in food allergy and eosinophilic gastrointestinal disorders, supported by federal, foundation, and industry funding. She is actively involved in the Food Allergy Research and Education (FARE) Clinical Network and FARE Neighborhoods Program, and serves as a Steering Committee member for the NIAID Consortium of Food Allergy Research (CoFAR). Her research interests also extend to evaluating mucosal immune responses in models of food allergy and eosinophilic gastrointestinal disorders. She has authored or co-authored 158 publications and has an h-index of 35, with 6,953 citations. Her work is recognized as high-impact, evidenced by her highly cited status.
Research Overview
Amy M. Scurlock, M.D. is an Associate Professor of Pediatrics at the University of Arkansas for Medical Sciences and Arkansas Children's Hospital. Dr. Scurlock is also a researcher at Arkansas Children's Hospital Research Institute. Dr. Scurlock received her M.D. in 1998 from the University of Arkansas for Medical Sciences. She completed a residency in Pediatrics at UAMS/ACH in 2001 and served as Chief Resident until 2002. She completed her Allergy-Immunology Fellowship Training at Duke University Medical Center in Durham North Carolina in 2004. Dr. Scurlock joined the UAMS faculty in August 2004 as a member of the Division of Pediatric Allergy/Immunology within the Department of Pediatrics. Dr. Scurlock's clinical interests include allergic and immunologic diseases such as food allergy, atopic dermatitis, eosinophilic esophagitis and primary immunodeficiency. She also has interest in newborn screening and long-term follow-up for infants with SCID and T-cell lymphopenia. Her research interests are focused on evaluation of mucosal immune responses in models of food allergy and eosinophilic gastrointestinal disorders. Dr. Scurlock is a member of the American Academy of Allergy Asthma and Immunology (AAAAI), Society for Mucosal Immunology, Society for Pediatric Research, Clinical Immunology Society, and American Academy of Pediatrics. She is board certified in both Pediatrics and Allergy-Immunology. Some of the UAMS College of Medicine faculty members provide pediatric patient care at Arkansas Children's Hospital. In addition, a wide range of pediatric services are provided in more than 35 subspecialties around Arkansas in locations such as the Schmieding Developmental Center in Springdale and the James L. Dennis Developmental Center in Little Rock. To make an appointment at Arkansas Children's Hospital, please call 501-364-4000.
Metrics
- h-index: 35
- Publications: 158
- Citations: 7,026
Selected Publications
-
Implementation of early peanut introduction among providers in a southern US state (2026)
-
Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergies (2025)
-
Introduction of allergenic foods after treatment with omalizumab (2025)
-
Introduction Of Allergenic Foods After Treatment With Omalizumab (2025)
-
Multicenter food protein–induced enterocolitis syndrome (FPIES) data collection: Leveraging a REDCap FPIES registry for improved clinical outcomes (2025)
-
Preparing Patients for Oral Immunotherapy (PPOINT): International Delphi consensus for procedural preparation and consent (2024)
-
Long-term walnut oral immunotherapy induces shifts in serum antibody binding patterns to walnut and cross-reactive tree nuts (2024)
-
Long-Term Follow-up after IMPACT Peanut Oral Immunotherapy Clinical Trial (2024)
-
Survey of Arkansas Pediatric Providers on the Application of the NIH/NIAID Addendum Guidelines for the Prevention of Peanut Allergy in the United States (2024)
-
Food insecurity and allergic diseases: A call to collective action (2023)
-
Peanut allergy (2023)
-
The SunBEAm birth cohort: Protocol design (2023)
-
Distinct trajectories distinguish antigen-specific T cells in peanut-allergic individuals undergoing oral immunotherapy (2023)
-
Efficacy and Safety of Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in Subjects Aged 1-3 Years With and Without Atopic Dermatitis in the EPITOPE Study (2023)
-
Food insecurity in children and adults with food allergies (2022)
Grants & Funding
- FARE Network UAMS ACHRI Flow Through Principal Investigator
- Immunoregulatory Networks in Chlamydia Genital Tract Infection NIH Principal Investigator
- No FP attached UAMS ACHRI Flow Through Principal Investigator
- FARE Network UAMS ACHRI Flow Through Principal Investigator
- No FP attached UAMS ACHRI Flow Through Principal Investigator
Collaboration Network
Top Collaborators
- Omalizumab for the Treatment of Multiple Food Allergies
- Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts
- Distinct trajectories distinguish antigen-specific T cells in peanut-allergic individuals undergoing oral immunotherapy
- Food insecurity and allergic diseases: A call to collective action
- Omalizumab for the Treatment of Multiple Food Allergy (OUtMATCH)
Showing 5 of 16 shared publications
- Omalizumab for the Treatment of Multiple Food Allergies
- Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results
- Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts
- Omalizumab for the Treatment of Multiple Food Allergy (OUtMATCH)
- Introduction of allergenic foods after treatment with omalizumab
Showing 5 of 12 shared publications
- Assessment of Anxiety, Depression and Resilience in Food-Allergic Adolescents and Primary Caregivers During the COVID-19 Pandemic
- A Multi-Center Evaluation of Anxiety, Depression, and Resilience in Food Allergic Adolescents and Primary Caregivers during the COVID-19 Pandemic
- A Multicenter Assessment of Food Allergy Quality of Life in Adolescents and Caregivers in Relation to Anxiety and Depression during the COVID-19 Pandemic
- Multicenter food protein–induced enterocolitis syndrome (FPIES) data collection: Leveraging a REDCap FPIES registry for improved clinical outcomes
- Prevalence of Atypical Food Protein Induced Enterocolitis Syndrome (FPIES) in a Regional, Multicenter FPIES Registry
Showing 5 of 11 shared publications
- Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results
- The SunBEAm birth cohort: Protocol design
- Food insecurity and allergic diseases: A call to collective action
- Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study)
- Multicenter food protein–induced enterocolitis syndrome (FPIES) data collection: Leveraging a REDCap FPIES registry for improved clinical outcomes
Showing 5 of 11 shared publications
- Omalizumab for the Treatment of Multiple Food Allergies
- Omalizumab for the Treatment of Multiple Food Allergy (OUtMATCH)
- Introduction of allergenic foods after treatment with omalizumab
- Treatment of Multi-Food Allergy with Omalizumab Compared to Omalizumab-Facilitated Multi-Allergen OIT
- Multicenter food protein–induced enterocolitis syndrome (FPIES) data collection: Leveraging a REDCap FPIES registry for improved clinical outcomes
Showing 5 of 11 shared publications
- Omalizumab for the Treatment of Multiple Food Allergies
- Allergen-specific T cells and clinical features of food allergy: Lessons from CoFAR immunotherapy cohorts
- The SunBEAm birth cohort: Protocol design
- Omalizumab for the Treatment of Multiple Food Allergy (OUtMATCH)
- Introduction of allergenic foods after treatment with omalizumab
Showing 5 of 8 shared publications
- Omalizumab for the Treatment of Multiple Food Allergies
- Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials
- Omalizumab for the Treatment of Multiple Food Allergy (OUtMATCH)
- Introduction of allergenic foods after treatment with omalizumab
- Treatment of Multi-Food Allergy with Omalizumab Compared to Omalizumab-Facilitated Multi-Allergen OIT
Showing 5 of 8 shared publications
- Omalizumab for the Treatment of Multiple Food Allergies
- Omalizumab for the Treatment of Multiple Food Allergy (OUtMATCH)
- Introduction of allergenic foods after treatment with omalizumab
- Treatment of Multi-Food Allergy with Omalizumab Compared to Omalizumab-Facilitated Multi-Allergen OIT
- Long-Term Follow-up after IMPACT Peanut Oral Immunotherapy Clinical Trial
Showing 5 of 8 shared publications
- Introduction of allergenic foods after treatment with omalizumab
- Treatment of Multi-Food Allergy with Omalizumab Compared to Omalizumab-Facilitated Multi-Allergen OIT
- Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study)
- Long-Term Follow-up after IMPACT Peanut Oral Immunotherapy Clinical Trial
- Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study
Showing 5 of 8 shared publications
- Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results
- Preparing Patients for Oral Immunotherapy (PPOINT): International Delphi consensus for procedural preparation and consent
- Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study)
- Long-Term Follow-up after IMPACT Peanut Oral Immunotherapy Clinical Trial
- Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study
Showing 5 of 7 shared publications
- Omalizumab for the Treatment of Multiple Food Allergies
- The SunBEAm birth cohort: Protocol design
- Omalizumab for the Treatment of Multiple Food Allergy (OUtMATCH)
- Introduction of allergenic foods after treatment with omalizumab
- Treatment of Multi-Food Allergy with Omalizumab Compared to Omalizumab-Facilitated Multi-Allergen OIT
Showing 5 of 7 shared publications
- Omalizumab for the Treatment of Multiple Food Allergies
- Omalizumab for the Treatment of Multiple Food Allergy (OUtMATCH)
- Introduction of allergenic foods after treatment with omalizumab
- Treatment of Multi-Food Allergy with Omalizumab Compared to Omalizumab-Facilitated Multi-Allergen OIT
- Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study)
Showing 5 of 7 shared publications
- Omalizumab for the Treatment of Multiple Food Allergies
- Omalizumab for the Treatment of Multiple Food Allergy (OUtMATCH)
- Introduction of allergenic foods after treatment with omalizumab
- Treatment of Multi-Food Allergy with Omalizumab Compared to Omalizumab-Facilitated Multi-Allergen OIT
- Long-Term Follow-up after IMPACT Peanut Oral Immunotherapy Clinical Trial
Showing 5 of 7 shared publications
- Omalizumab for the Treatment of Multiple Food Allergies
- Omalizumab for the Treatment of Multiple Food Allergy (OUtMATCH)
- Introduction of allergenic foods after treatment with omalizumab
- Treatment of Multi-Food Allergy with Omalizumab Compared to Omalizumab-Facilitated Multi-Allergen OIT
- Introduction Of Allergenic Foods After Treatment With Omalizumab
Showing 5 of 7 shared publications
- Multicenter food protein–induced enterocolitis syndrome (FPIES) data collection: Leveraging a REDCap FPIES registry for improved clinical outcomes
- Prevalence of Atypical Food Protein Induced Enterocolitis Syndrome (FPIES) in a Regional, Multicenter FPIES Registry
- Food Protein-induced Enterocolitis (FPIES) to Peanut: A Multicenter Cohort Study
- Characteristics of Egg-induced FPIES in the Southwest United States
- Epidemiology of Food Protein-Induced Enterocolitis in a Regional Multicenter Research Cohort
Showing 5 of 7 shared publications
Similar Researchers
Based on overlapping research topics